Health & Biotech
Melbourne biotech Mesoblast (ASX:MSB) is attempting to commercialise a stem cell treatment known as remestemcel-L for conditions such as acute graft versus host disease, advanced heart failure and chronic lower back pain due to degenerative disc disease. Mesoblast acquired remestemcel-L from US-based Osiris Therapeutics in 2013.
Mesoblast’s proprietary process selects precursors and stem cells from the bone marrow of healthy adults, creating a master cell bank. This cell bank is then expanded into thousands of doses for off-the-shelf use, without the need for tissue matching.
Mesoblast debuted on the ASX in 2004 and reached a peak valuation of $2.5 billion in 2011. The company dual listed on the Nasdaq in November 2015, accompanied by a $US63m capital raising.
The company was dealt a blow in October 2020 when the US Food and Drug Administration declined to approve remestemcel-L for the treatment of acute graft versus host disease in children, instead asking for more data. Mesoblast is expected to dispute the FDA’s decision.
Mesoblast licensed remestemcel-L to Swiss pharmaceutical giant Novartis in November 2020 for indications other than graft versus host disease, a devastating complication from bone marrow transplants.
RELATED STOCKHEAD STORIES
Health & Biotech
Muted market reaction to long-awaited Mesoblast back pain study
Health & Biotech
Clinical Trials Tracker: 2022 and beyond
News
Stonkhead: Why do millionaire investors bother selling courses?
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
Weekly ASX small cap wrap: Which ASX stock is hosting a Christmas sleepover?
News
ASX Small Cap Lunch Wrap: Who’s getting the hell out of Dodge today?
Health & Biotech
Mesoblast shares smashed after COVID study setback
News
10 at 10: These ASX stocks have grabbed the most attention this morning
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Mesoblast shares fall on trial’s mixed results with heart injection treatment
Health & Biotech
More evidence for Mesoblast stem cell therapy in graft-versus-host disease
News
ScoPo’s powerplays: ‘Santa is smiling on the markets’
Health & Biotech
Who else on the ASX joins Mesoblast in the fight against ARDS and where are they at?
Health & Biotech
Mesoblast COVID-19 therapy granted fast-track designation
Health & Biotech
Mesoblast in potential $1.7bn partnership with Novartis to develop remestemcel-L
Health & Biotech
The ASX biotech companies that lost puff on Pfizer vaccine news
Health & Biotech